Joel David Mayersohn - 28 Jul 2025 Form 4 Insider Report for CITIUS ONCOLOGY, INC. (CTOR)

Reporting relationship: Director
Issuer ticker: CTOR
Reported as of: 28 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Aug 2025, 17:02:07 UTC
Prior SEC filing: 16 Dec 2024
Next SEC filing: 01 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Alexander M. Donaldson, by Power of Attorney

Key filing fact

Joel David Mayersohn filed Form 4 for CITIUS ONCOLOGY, INC. (CTOR) on 07 Aug 2025.

Key facts

This page summarizes Joel David Mayersohn's Form 4 filing for CITIUS ONCOLOGY, INC. (CTOR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Aug 2025, 17:02.

Change

Previous filing in this sequence was filed on 16 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001588395 Primary reporting owner

Mayersohn Joel David

Relationship: Director
Address: C/O CITIUS ONCOLOGY, INC., 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD
Signature: /s/ Alexander M. Donaldson, by Power of Attorney
Signature date: 07 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTOR transaction

Common Stock

Other

Transaction value: $0
Shares: +21,228
Change %
Price: $0.000000
Shares after: 21,228
Date: 28 Jul 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTOR holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 250,000
Date: 28 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250,000
Exercise price: $1.07
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares were acquired through a distribution in kind to limited partners of 10XYZ Holdings, which was the Sponsor of TenX Keane Acquisition ("TenX"), the legacy entity of Citius Oncology, Inc.

Footnote F2

The options were granted on December 12, 2024. The options will vest 100% on the one-year anniversary of the grant date, provided that the Optionee provides Continuous Service to the Company as of the vesting date.